Biophytis (BPTSY) Competitors $3.36 0.00 (0.00%) As of 04/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock BPTSY vs. CMND, OGEN, APM, ADIL, ALLR, SONN, EVOK, GLTO, CNSP, and KZIAShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Clearmind Medicine (CMND), Oragenics (OGEN), Aptorum Group (APM), Adial Pharmaceuticals (ADIL), Allarity Therapeutics (ALLR), Sonnet BioTherapeutics (SONN), Evoke Pharma (EVOK), Galecto (GLTO), CNS Pharmaceuticals (CNSP), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Clearmind Medicine Oragenics Aptorum Group Adial Pharmaceuticals Allarity Therapeutics Sonnet BioTherapeutics Evoke Pharma Galecto CNS Pharmaceuticals Kazia Therapeutics Biophytis (NASDAQ:BPTSY) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Does the media favor BPTSY or CMND? In the previous week, Clearmind Medicine had 4 more articles in the media than Biophytis. MarketBeat recorded 4 mentions for Clearmind Medicine and 0 mentions for Biophytis. Clearmind Medicine's average media sentiment score of 0.20 beat Biophytis' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media. Company Overall Sentiment Biophytis Neutral Clearmind Medicine Neutral Which has better earnings & valuation, BPTSY or CMND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiophytisN/AN/A-$18.43MN/AN/AClearmind MedicineN/AN/A-$5.26M-$1.22-0.79 Do insiders and institutionals believe in BPTSY or CMND? 0.1% of Biophytis shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BPTSY or CMND more profitable? Biophytis' return on equity of 0.00% beat Clearmind Medicine's return on equity.Company Net Margins Return on Equity Return on Assets BiophytisN/A N/A N/A Clearmind Medicine N/A -129.21%-61.15% Which has more volatility & risk, BPTSY or CMND? Biophytis has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Does the MarketBeat Community believe in BPTSY or CMND? Biophytis and Clearmind Medicine both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformBiophytisN/AN/AClearmind MedicineN/AN/A SummaryBiophytis and Clearmind Medicine tied by winning 4 of the 8 factors compared between the two stocks. Remove Ads Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18M$6.10B$5.08B$6.91BDividend YieldN/A2.91%5.34%4.23%P/E RatioN/A6.5321.2317.05Price / SalesN/A185.43346.5985.96Price / CashN/A65.6738.1534.64Price / Book-0.215.356.023.66Net Income-$18.43M$141.19M$3.19B$247.27M7 Day PerformanceN/A-12.28%-8.85%-9.80%1 Month PerformanceN/A-20.11%-6.82%-12.84%1 Year PerformanceN/A-22.71%0.59%-10.68% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$3.36flatN/AN/A$1.18MN/A0.0030News CoverageCMNDClearmind Medicine0.6817 of 5 stars$1.04-3.3%N/A-14.5%$4.56MN/A-0.55N/APositive NewsGap DownOGENOragenicsN/A$0.21-2.8%N/A-86.6%$4.51M$40,000.00-0.035Gap DownAPMAptorum Group0.8819 of 5 stars$0.84-5.1%N/A-91.2%$4.35M$430,000.000.0030Gap DownADILAdial Pharmaceuticals2.1726 of 5 stars$0.63-5.0%$8.00+1,161.4%-32.7%$4.17MN/A-0.1920Positive NewsALLRAllarity Therapeutics0.6228 of 5 stars$0.94-9.6%N/A-99.4%$4.17MN/A0.0010SONNSonnet BioTherapeutics2.0079 of 5 stars$1.34+2.3%$20.00+1,392.5%-37.8%$4.11M$1M0.0010Analyst ForecastGap DownEVOKEvoke Pharma0.3668 of 5 stars$2.75-1.4%N/A-69.2%$4.11M$10.25M-0.254GLTOGalecto2.0769 of 5 stars$3.10-9.4%$10.00+222.6%-87.4%$4.10MN/A-0.1640CNSPCNS Pharmaceuticals1.2671 of 5 stars$1.36+4.6%$25.00+1,738.2%-99.8%$4.00MN/A-0.025Gap DownKZIAKazia Therapeutics1.9573 of 5 stars$0.78-11.0%$11.50+1,368.9%-82.9%$3.94M$2.31M0.0012 Remove Ads Related Companies and Tools Related Companies Clearmind Medicine Alternatives Oragenics Alternatives Aptorum Group Alternatives Adial Pharmaceuticals Alternatives Allarity Therapeutics Alternatives Sonnet BioTherapeutics Alternatives Evoke Pharma Alternatives Galecto Alternatives CNS Pharmaceuticals Alternatives Kazia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 4/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPTSY Stock Free BPTSY Stock Alerts